pharma

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares jumped more than 40% after the pharma company, together with Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that the APOLLO Phase 3 study of patisiran, an investigatio..

Walgreens Received Regulatory Clearance to Acquire     Rite Aid

Walgreens Received Regulatory Clearance to Acquire Rite Aid

Walgreens Boots Alliance Inc (NASDAQ: WBA) has received the regulatory clearance required for the acquisition of Rite Aid Corporation (NYSE: RAD) for 4.375 billion in cash. Tuesday Walgreens announced that the amended and restated asset purchase agr..

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..

Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint

Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint

Sage Therapeutics (NASDAQ: SAGE) shares are down about 15% after the a clinical-stage biopharmaceutical company announced the results from the Phase 3 STATUS Trial of did not meet the primary endpoint. The trial of brexanolone (SAGE-547) in the trea..

Insmed Incorporated Shares Jumped More than 100% After Positive Clinical Trial Data

Insmed Incorporated Shares Jumped More than 100% After Positive Clinical Trial Data

Insmed Incorporated (NASDAQ: INSM) stock jumped about 113% on Tuesday, after the biopharmaceutical company announced top-line data from its Phase 3 CONVERT study.The company announced that the global CONVERT study met its primary endpoint of culture..

Novartis Immunocellular Therapy Approved by FDA

Novartis Immunocellular Therapy Approved by FDA

Novartis AG (NYSE: NVS) announced Wednesday that the US Food and Drug Administration (FDA) has approved Kymriah (TM)(tisagenlecleucel) suspension for intravenous infusion, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment..

Catalent Inc Shares Up After Strong Earnings

Catalent Inc Shares Up After Strong Earnings

Catalent Inc (NYSE: CTLT) shares jumped more than 13% Tuesday after the company announced fourth quarter and full year 2017 results. Catalent provides delivery technologies and development solutions for drugs, biologic, and consumer and animal healt..